Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient

被引：7
|
作者：
Ito, Munehiro [1 ]
Kanda, Shintaro [1 ]
Yoshida, Tatsuya [1 ]
Okuma, Yusuke [1 ]
Jo, Hitomi [1 ]
Fukuhara, Suguru [2 ]
Maeshima, Akiko Miyagi [3 ]
Ohe, Yuichiro [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Hematol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Dept Diagnost Pathol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
来源：
LUNG CANCER | 2020年 / 146卷
关键词：
immune-related thrombocytopenia; pembrolizumab; eltrombopag olamine; rituximab; non-small cell lung cancer; PURPURA;
D O I：
10.1016/j.lungcan.2020.05.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objectives: Immune checkpoint inhibitors (ICIs) have shown antitumor activity against a wide variety of malignancies. ICI-induced immune-related thrombocytopenia is a rare immune-related adverse event (irAE). Little is known about the treatment of refractory immune-related thrombocytopenia in non-small cell lung cancer (NSCLC) patients treated with pembrolizumab. Results: We report the case of a patient with advanced NSCLC complicated by pembrolizumab-induced refractory immune-related thrombocytopenia who showed remarkable improvement in the thrombocytopenia in response to eltrombopag olamine treatment. Conclusion: Eltrombopag olamine can be a viable treatment option for refractory pembrolizumab-induced immune-related thrombocytopenia in an NSCLC patient.
引用
收藏
页码：362 / 365
页数：4
相关论文
共 50 条
  • [41] Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer
    Thompson, Leah L.
    Nadelmann, Emily R.
    Blum, Amy E.
    Yoon, Jaewon
    Polyakov, Nicole J.
    Kagan, Ruth D.
    Gainor, Justin F.
    Mooradian, Meghan J.
    Chen, Steven T.
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 13 - 16
  • [42] Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer
    Inoue, Yusuke
    Inui, Naoki
    Karayama, Masato
    Asada, Kazuhiro
    Matsuura, Shun
    Ikeda, Masaki
    Uto, Tomohiro
    Fujii, Masato
    Hashimoto, Dai
    Matsui, Takashi
    Matsuda, Hiroyuki
    Inami, Nao
    Toyoshima, Mikio
    Kaida, Yusuke
    Yasui, Hideki
    Hozumi, Hironao
    Suzuki, Yuzo
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Fujisawa, Tomoyuki
    Suda, Takafumi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 2963 - 2974
  • [43] Immune-Related Genomic Features in Non-Small-Cell Lung Cancer
    Wang, Z.
    Lu, B.
    Xu, T.
    Wei, C.
    Ma, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1208 - S1208
  • [44] Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
    Shankar, Bairavi
    Zhang, Jiajia
    Naqash, Abdul Rafeh
    Forde, Patrick M.
    Feliciano, Josephine L.
    Marrone, Kristen A.
    Ettinger, David S.
    Hann, Christine L.
    Brahmer, Julie R.
    Ricciuti, Biagio
    Owen, Dwight
    Toi, Yukihiro
    Walker, Paul
    Otterson, Gregory A.
    Patel, Sandip H.
    Sugawara, Shunichi
    Naidoo, Jarushka
    JAMA ONCOLOGY, 2020, 6 (12) : 1952 - 1956
  • [45] The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
    Philip Bredin
    Jarushka Naidoo
    Cancer and Metastasis Reviews, 2022, 41 : 347 - 366
  • [46] The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
    Bredin, Philip
    Naidoo, Jarushka
    CANCER AND METASTASIS REVIEWS, 2022, 41 (02) : 347 - 366
  • [47] Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer
    Yusuke Inoue
    Naoki Inui
    Masato Karayama
    Kazuhiro Asada
    Shun Matsuura
    Masaki Ikeda
    Tomohiro Uto
    Masato Fujii
    Dai Hashimoto
    Takashi Matsui
    Hiroyuki Matsuda
    Nao Inami
    Mikio Toyoshima
    Yusuke Kaida
    Hideki Yasui
    Hironao Hozumi
    Yuzo Suzuki
    Kazuki Furuhashi
    Noriyuki Enomoto
    Tomoyuki Fujisawa
    Takafumi Suda
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2963 - 2974
  • [48] Pembrolizumab-Induced Immune-Mediated Hepatitis and Concurrent Hepatitis B Reactivation in a Patient With Non-Small Cell Lung Cancer
    Kundumadam, Shanker
    Mohamad, Bashar
    Muthusamy, Arun
    Kathi, Pradeep R.
    Ehrinpreis, Murray N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (11)
  • [49] Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study
    Egami, Saeka
    Kawazoe, Hitoshi
    Hashimoto, Hironobu
    Uozumi, Ryuji
    Arami, Toko
    Sakiyama, Naomi
    Ohe, Yuichiro
    Nakada, Hideo
    Aomori, Tohru
    Ikemura, Shinnosuke
    Fukunaga, Koichi
    Yamaguchi, Masakazu
    Nakamura, Tomonori
    JOURNAL OF CANCER, 2021, 12 (07): : 2105 - 2112
  • [50] Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer
    Fujita, Tetsuo
    Hayama, Nami
    Kuroki, Tsuguko
    Shiraishi, Yuka
    Amano, Hiroyuki
    Nakamura, Makoto
    Hirano, Satoshi
    Aramaki, Nao
    Ichinose, Shuji
    Shimizu, Shinichiro
    Tabeta, Hiroshi
    Nakamura, Sukeyuki
    THORACIC CANCER, 2019, 10 (11) : 2179 - 2182
12345